Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 8, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific securities transaction rather than a financial report.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a single transaction involving an increase in the notional interest in GSK American Depositary Shares (ADSs) held by Dr. K. Slaoui (PCA of Dr. M. M. Slaoui, Chairman, Global Vaccines). This increase resulted from the allocation of ADSs following the revaluation of the cash element of a notional investment within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly reports the mechanics of the transaction:
- Instrument: GSK American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Date: November 7, 2016.
- Price: $38.84 per ADS.
- Volume: 1 ADS.
Investor Verification Points
- Verify the identity of the reporting individual (Dr. K. Slaoui) and their relationship to the PDMR (Dr. M. M. Slaoui).
- Confirm the transaction was a non-discretionary allocation resulting from a 401(K) plan revaluation rather than an open market purchase.
- Note that the transaction volume was minimal (1 ADS) and does not indicate a significant change in ownership structure.